CCCC today
$2.73-$0.04 (-1.62%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $2.59
Key levels
Resistance$3.23
Resistance$2.90
Support$2.59
Support$2.30
Latest news & SEC filings
DealC4 Therapeutics pulls in $125 million via share sale
AnalystGuggenheim keeps Buy rating on C4 Therapeutics, cuts price target to $6
EarningsC4 Therapeutics Posts Q3 2026 Financials
EarningsC4 Therapeutics posts $0.16 quarterly loss, revenue $8.468M
All CCCC news →About C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company that designs small-molecule protein degraders using its TORPEDO platform. Its lead candidates are cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant non-small-cell lung cancer. It also pursues preclinical programs in inflammation, neuroinflammation, and neurodegeneration, and collaborates with Merck KGaA and Roche.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
C4 Therapeutics, Inc. (CCCC)
What Is the Price Target for CCCC?
SEPT Low Target
$10.00
SEPT Mid Target
$10.50
SEPT High Target
$11.00
Analyst Consensus
$10.50
Is CCCC a Buy or Sell Right Now?
Thesis
- •Revenue growing 1.0% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CCCC.
Start Free Trial →Is CCCC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.11
25
Moat Score
NONE
4/9
Piotroski Score
-1.5
Altman Z-Score
What Is Smart Money Doing with CCCC?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Adams Kendra | officer | Buy | 6,250 | - | Sep 18, 2026 |
| Adams Kendra | officer | Sale | 2,775 | $9K | Sep 18, 2026 |
| Anderson Kenneth Carl | director | Buy | 1,070 | $2K | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CCCC Growth Story
Revenue YoY
1.0%
3yr Revenue CAGR
5.0%
EPS Growth YoY
16.45%
FCF Growth YoY
-52.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for CCCC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CCCC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:14:45 | $2.73 | 1,000 | $$3K | SELL |
| 16:09:26 | $2.73 | 1,150 | $$3K | SELL |
| 15:57:15 | $2.74 | 1,444 | $$4K | SELL |
| 15:43:17 | $2.78 | 1,210 | $$3K | BUY |
| 15:38:13 | $2.79 | 5,000 | $$14K | SELL |
5 dark pool trades shown · $$27K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for C4 Therapeutics, Inc. (CCCC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CCCC — frequently asked questions
What is CCCC stock price today?
C4 Therapeutics, Inc. (CCCC) is at $2.73, down 1.62% (-$0.04) at the Nov 13, 2026 close.
Why is CCCC stock moving today?
Latest CCCC news — Nov 7, 2026: C4 Therapeutics pulls in $125 million via share sale · Nov 6, 2026: Guggenheim keeps Buy rating on C4 Therapeutics, cuts price target to $6
What is the CCCC price target?
The average analyst price target for CCCC is $10.50, ranging from $10 to $11, based on 2 analysts. Latest: Lake Street initiates on Oct 28, 2026.
What do analysts rate CCCC?
Analyst ratings for CCCC: 0 Buy, 2 Hold, 1 Sell — consensus Hold.
Did CCCC beat earnings?
CCCC last reported on Aug 11, 2026: EPS -$0.18 vs -$0.23 expected — a beat of 20.5%.
Does CCCC pay a dividend?
CCCC does not currently pay a dividend.
What are CCCC support and resistance levels?
Support: $2.59, $2.30, $2.02. Resistance: $2.90, $3.23, $3.53.
What are insiders doing with CCCC?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on CCCC?
Nov 7, 2026: C4 Therapeutics pulls in $125 million via share sale · Nov 6, 2026: Guggenheim keeps Buy rating on C4 Therapeutics, cuts price target to $6 · Nov 5, 2026: C4 Therapeutics Posts Q3 2026 Financials